Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab

Bibliographic Details
Main Authors: Falchook, Gerald S, Wheler, Jennifer J, Naing, Aung, Jackson, Edward F, Janku, Filip, Hong, David, Ng, Chaan S, Tannir, Nizar M, Lawhorn, Kristie N, Huang, Mei, Angelo, Laura S, Vishwamitra, Deeksha, Hess, Kenneth, Howard, Adrienne N, Parkhurst, Kristin L, Amin, Hesham M, Kurzrock, Razelle
Format: Online
Language:English
Published: Impact Journals LLC 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279372/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279372/

Similar Items